GSC
IMDX

Ground Swell Capital’s Insight Molecular Diagnostics IMDX Stock Holding History

Ground Swell Capital’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,915
Closed -$26K – 226
2024
Q4 		$26K Buy
+10,915
New +$29.7K 0.04% 109

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIA
Wealthedge Investment Advisors New York $294M AUM 20.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ground Swell Capital's IMDX Position: Q1 2025 in Review

Ground Swell Capital sold out of Insight Molecular Diagnostics (IMDX) in Q1 2025, closing a stake of 10,915 shares — an estimated $26K sold.

Ground Swell Capital first reported a position in IMDX in Q4 2024 and held it in 1 quarter. The position peaked at $26K in Q4 2024. 30 funds tracked by Wall St. Rank hold IMDX as of Q1 2025.

  • Ground Swell Capital reported no remaining Insight Molecular Diagnostics position as of Q1 2025 after selling out during the quarter.
  • Ground Swell Capital sold 10,915 Insight Molecular Diagnostics shares in Q1 2025, an estimated $26K.
  • Ground Swell Capital first reported a position in Insight Molecular Diagnostics in Q4 2024 and held it in 1 quarter.
  • Ground Swell Capital's Insight Molecular Diagnostics position peaked at $26K in Q4 2024.
  • 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2025.

Based on Ground Swell Capital's 13F filing for Q1 2025, filed 13 May 2025.